Sight Diagnostics, a Tel Aviv, Israel-based company working to provide patients with lab-grade blood testing results in minutes, raised $27.8m in Series C funding.
The round was led by Longliv Ventures, with participation from OurCrowd, Go Capital, New Alliance Capital, Jack Nicklaus II, Steven Esrick, and an additional major medical equipment manufacturer.
The company will use the funds to continue the global expansion of its lab-grade point-of-care blood diagnostics system, OLO, continue its regulatory efforts in the US, and further its R&D to expand its menu of diagnostic tests.
Led by Yossi Pollak, CEO, and Sarah Levy, CTO, Sight provides patients with access to pain-free diagnostic testing that delivers results in minutes instead of days. To do so, the company has developed an artificial intelligence-driven platform for blood analysis and infectious disease diagnostics based on its methods for ‘digitizing’ blood. The company’s platform was first deployed in 2014 to detect malaria, for which over 600,000 tests have been sold across 25 countries. The company’s newest offering, OLO, brings lab-grade Complete Blood Counts (CBCs) to the point-of-care and is now available for purchase in the EU.
In the United States, OLO is an investigational system and is not yet available for sale.